Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University Under Section 3 of UGC Act - 1956, Elite Status and Center of Excellence, Govt. of Maharashtra, Mumbai 400 019, India.
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University Under Section 3 of UGC Act - 1956, Elite Status and Center of Excellence, Govt. of Maharashtra, Mumbai 400 019, India.
Eur J Pharm Sci. 2017 Sep 30;107:78-86. doi: 10.1016/j.ejps.2017.06.027. Epub 2017 Jun 16.
Poly(lactic-co-glycolic acid) microspheres loaded with cholecalciferol (CL), more bioactive form of vitamin D was developed as an injectable controlled drug release system and was evaluated for its feasibility of once a month delivery. The CL loaded microspheres (CL-MS) were prepared by simple oil in water (O/W) emulsion-solvent evaporation technique incorporated with a stabilizer, Tocopherol Succinate (TS). Different formulation as well as process parameters were investigated namely concentration of emulsifier, concentration of stabilizer and drug: polymer mass ratios. The prepared CL-MS were evaluated for particle size, drug loading, in-vitro drug release and in-vivo pharmacokinetics in rats. The optimized formulation was found to have a mean particle size of 28.62±0.26μm, Encapsulation Efficiency (EE) of 94.4±5.4% and drug loading of 5.19±0.29% with CL:TS ratio of 2:1. It was found that the EE drastically decreased (26±5.9%) in the absence of stabilizer (TS) indicating its role in stabilization of CL during formulation. DSC and XRD studies indicated that CL existed in an amorphous structure in the polymer matrix. SEM of the CL-MS revealed the spherical morphology and confirmed the particle size. In-vitro release showed that the CL release from CL-MS followed near zero-order drug release kinetics over nearly 1month. In-vivo pharmacokinetic study of CL-MS showed higher t (239±27.5h) compared to oily CL depot (32.7±4.8h) with sustained release of CL plasma concentration for 1month. The labile CL could thus be effectively encapsulated and protected against degradation during microspheres formulation, storage and release in presence of stabilizer. This novel CL loaded PLGA MS is stable and may have great potential for clinical use.
载有胆钙化醇(CL)的聚(乳酸-共-乙醇酸)微球作为一种可注射的控释药物释放系统被开发出来,并评估了其每月一次给药的可行性。通过简单的油包水(O/W)乳液-溶剂蒸发技术制备了载有 CL 的微球(CL-MS),并加入稳定剂生育酚琥珀酸酯(TS)。研究了不同的配方和工艺参数,即乳化剂浓度、稳定剂浓度和药物:聚合物质量比。对制备的 CL-MS 进行了粒径、载药量、体外药物释放和大鼠体内药代动力学评价。优化的配方具有平均粒径为 28.62±0.26μm、包封效率(EE)为 94.4±5.4%和载药量为 5.19±0.29%,CL:TS 比为 2:1。结果发现,在没有稳定剂(TS)的情况下,EE 急剧下降(26±5.9%),表明其在配方过程中对 CL 的稳定作用。DSC 和 XRD 研究表明,CL 以无定形结构存在于聚合物基质中。CL-MS 的 SEM 显示了球形形态,并证实了粒径。体外释放结果表明,CL-MS 中 CL 的释放遵循近零级药物释放动力学,近 1 个月。CL-MS 的体内药代动力学研究表明,与油性 CL 库(32.7±4.8h)相比,CL 的 t(239±27.5h)更高,CL 血浆浓度持续释放 1 个月。因此,在存在稳定剂的情况下,不稳定的 CL 可以有效地包封并防止在微球配方、储存和释放过程中降解。这种新型的载有 CL 的 PLGA MS 是稳定的,可能具有很大的临床应用潜力。